Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital

Investment analysts at D. Boral Capital started coverage on shares of Estrella Immunopharma (NASDAQ:ESLA) in a report released on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $16.00 price target on the stock.

Estrella Immunopharma Trading Up 8.0 %

ESLA opened at $1.22 on Tuesday. Estrella Immunopharma has a twelve month low of $0.63 and a twelve month high of $3.23. The firm has a market capitalization of $44.14 million, a PE ratio of -4.69 and a beta of 0.41. The firm’s 50-day moving average price is $1.16 and its 200 day moving average price is $1.10.

Institutional Investors Weigh In On Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC increased its position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,418 shares of the company’s stock after buying an additional 16,862 shares during the quarter. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.